Nutraceuticals enriched with palmitoylethanolamide (PEA), myrrh, and alpha-lipoic acid are effective in controlling symptoms and growth of cyst in women with endometriosis.
On behalf of the findings of a
recently published multi-centre study, palmitoylethanolamide (PEA), myrrh, and
alpha-lipoic acid can serve as useful alternatives to control chronic pelvic
pain and dysmenorrheal.
The women with endometriosis showed higher rates of chronic pelvic pain and dysmenorrhea, with the incidence ranging from 5 to 10% of the general population and 35% to 50% of infertile women. This necessitates integrated approaches with anti-inflammatory medications with lifestyle changes, comprising attention to diet. However, traditional anti-inflammatory medicines over the long term are not promising as long term use of these drugs may cause side effects. Therefore, the current analysis focused on natural substances with anti-inflammatory properties, whose mechanisms of action are synergistically linked with one another.
One such combination is the myrrh, alpha-lipoicc acid, and PEA, whose activity is so intense that it may replace the application of anti-inflammatory medicines. This study involved a total of sixty women with endometriosis and chronic pelvic pain who obtained neutraceutical product based on 300 mg PEA, 100 mg myrrh, and 400 mg alpha-lipoic acid, at a dose of two tablets every day for the six months.
Minerva Ginecologica
https://www.minervamedica.it/en/journals/minerva-ginecologica/article.php?cod=R09Y9999N00A19012801
Role of a natural integrator based on lipoic acid, palmitoylethanolamide and myrrh in the treatment of chronic pelvic pain and endometriosis.
Vincenzo DE LEO et al.
Comments (0)